Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FTAI Aviation Ltd (FTAI) vs Medpace Holdings Inc (MEDP) Price & Performance

FTAI Aviation LtdTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

FTAI Aviation Ltd vs Medpace Holdings Inc — how do they compare? FTAI Aviation Ltd trades at $229.96 (market cap $23.17B), while Medpace Holdings Inc trades at $598.69 (market cap $16.90B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 0.89% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

FTAIMEDP
Market Cap
$23.17B$16.90B
Sector
IndustrialsTechnology
52-Week High
$310.04$620.59
52-Week Low
$140.40$393.42
Enterprise Value
$26.29B$16.52B
Dividend Yield
0.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FTAI Aviation Ltd

FTAI Aviation trades at $229.01, up 6.52% today, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a 15.94% net margin and 167.93% ROE, but valuation ratios are elevated (P/E 49.26, P/B 57.36). Recent Q2 2026 earnings missed expectations at $1.13 per share versus $1.38 expected, though revenue grew to $3.1B in 2026. The company announced a strategic collaboration for Boeing 737-800 freighters and a $1.465B gas turbine order, signaling growth initiatives.

Outlook remains positive with 100% analyst buy ratings and a $341.67 consensus price target, implying 49% upside. Key risks include earnings misses, declining EBITDA margins, and negative operating cash flow. The power segment's data center potential offers growth, but execution on guidance and leasing transition are critical for sustained performance.

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About FTAI Aviation Ltd

FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.

Read more on FTAI

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP